Phase I/II trials of anti-PD-1 and anti-CTLA-4 checkpoint inhibitors for HCC have demonstrated treatment responses; unfortunately, though, the response rates remain low3,4,5,6,8. The gene discussed is CTLA4; the disease is hepatocellular carcinoma.